A case report of a very late response to 5-azacytidine in a patient with lower risk myelodysplastic syndrome: Time to update treatment guidelines for lower risk patients

RATIONALE: The hypomethylating agent 5-azacytidine has been approved in Europe for patients with intermediate 2 and high (i.e., higher) risk myelodysplastic syndrome according to the International Prognostic Scoring System (IPSS). A total of 91% of all first responses in higher risk patients occur w...

Descripción completa

Detalles Bibliográficos
Autores principales: Spetsieris, Nikolaos, Diamantopoulos, Panagiotis, Zervakis, Konstantinos, Giannakopoulou, Nefeli, Rougala, Niki, Garefalakis, Georgios, Skarlatou, Vasiliki, Viniou, Nora-Athina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944567/
https://www.ncbi.nlm.nih.gov/pubmed/29703015
http://dx.doi.org/10.1097/MD.0000000000010505

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944567/
https://www.ncbi.nlm.nih.gov/pubmed/29703015
http://dx.doi.org/10.1097/MD.0000000000010505

Ejemplares similares